nmt2

PCLX-001 is a small-molecule compound that acts as an orally active inhibitor of N-myristoyltransferase (NMT), specifically targeting NMT1 and NMT2 with IC50 values of 5 nM and 8 nM, respectively. This compound demonstrates anti-tumor effects and effectively inhibits the early signaling of B-cell receptor (BCR). Consequently, PCLX-001 is a valuable tool for researching B-cell malignancies [1] [2].

IMP-1088 is a potent inhibitor of human N-myristoyltransferases NMT1 and NMT2 dual.

DNMT2-IN-1 (compound 80) is a novel DNMT2 (DNA methyltransferase 2) inhibitor with an IC50 of 1.2 μM, intended for research in neurological and metabolic disorders or cancer.

DNMT2-IN-2 is a selective inhibitor of DNA methyltransferase 2 (DNMT2) with a KD value of 3.04 μM. It targets a concealed allosteric binding site of DNMT2 and reduces m5C levels in tRNA of MOLM-13 cells. This compound works synergistically with Doxorubicin to impair cell viability and is applicable in cancer research, including studies of cervical cancer and leukemia.

Luzindole (N-0774) is a selective melatonin receptor antagonist that inhibits experimental autoimmune encephalomyelitis and exhibits antidepressant-like activity. It preferentially targets MT2 (Mel1b) over MT1 (Mel1a), with Ki values of 10.2 nM for human MT2 and 158 nM for MT1.

TIK-301 is a chlorinated melatonin derivative and a potent, high-affinity, and orally active melatonin MT1 and MT2 receptors agonist (Kis: 0.081 nM and 0.042 nM, respectively). TIK-301 is also a 5-HT2B/5-HT2C receptor antagonist with antidepressant action. TIK-301 has the potential for sleep disorders and other circadian rhythm disorders treatment.